{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:30:59Z","timestamp":1793745059732,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Institut National du Cancer (INCa)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0571-y","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T12:24:05Z","timestamp":1487334245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry"],"prefix":"10.1186","volume":"12","author":[{"name":"on behalf of the RENAPE Network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Villeneuve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Passot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. N.","family":"Gilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"571_CR1","first-page":"115","volume":"1","author":"Y Zhong","year":"2012","unstructured":"Zhong Y, Deng M, Xu R, et al. Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: a review of the literature. Intractable Rare Dis Res. 2012;1:115\u201321.","journal-title":"Intractable Rare Dis Res"},{"key":"571_CR2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejso.2007.04.002","volume":"34","author":"RM Smeenk","year":"2008","unstructured":"Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196\u2013201.","journal-title":"Eur J Surg Oncol"},{"key":"571_CR3","first-page":"233","volume":"30","author":"PH Sugarbaker","year":"1996","unstructured":"Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233\u201380.","journal-title":"Adv Surg"},{"key":"571_CR4","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/1097-0142(19901001)66:7<1636::AID-CNCR2820660731>3.0.CO;2-N","volume":"66","author":"WJ Mann Jr","year":"1990","unstructured":"Mann Jr WJ, Wagner J, Chumas J, Chalas E. The management of pseudomyxoma peritonei. Cancer. 1990;66:1636\u201340.","journal-title":"Cancer"},{"key":"571_CR5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.annpat.2014.01.012","volume":"34","author":"P Dartigues","year":"2014","unstructured":"Dartigues P, Isaac S, Villeneuve L, et al. Peritoneal pseudomyxoma: an overview emphasizing pathological assessment and therapeutic strategies. Ann Pathol. 2014;34:14\u201325.","journal-title":"Ann Pathol"},{"key":"571_CR6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejso.2013.12.021","volume":"40","author":"P Taflampas","year":"2014","unstructured":"Taflampas P, Dayal S, Chandrakumaran K, et al. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients. Eur J Surg Oncol. 2014;40:515\u201320.","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl 1","key":"571_CR7","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/modpathol.2014.129","volume":"28","author":"J Misdraji","year":"2015","unstructured":"Misdraji J. Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei. Mod Pathol. 2015;28 Suppl 1:S67\u201379.","journal-title":"Mod Pathol"},{"key":"571_CR8","volume-title":"WHO classification of tumours of the digestive system","author":"FT Bosmann","year":"2010","unstructured":"Bosmann FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC; 2010."},{"key":"571_CR9","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449\u201356.","journal-title":"J Clin Oncol"},{"key":"571_CR10","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.3747\/co.23.2831","volume":"23","author":"J Spiliotis","year":"2016","unstructured":"Spiliotis J, Halkia E, de Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol. 2016;23:e266\u2013275.","journal-title":"Curr Oncol"},{"key":"571_CR11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4251\/wjgo.v2.i1.44","volume":"2","author":"KE Bevan","year":"2010","unstructured":"Bevan KE, Mohamed F, Moran BJ. Pseudomyxoma peritonei. World J Gastrointest Oncol. 2010;2:44\u201350.","journal-title":"World J Gastrointest Oncol"},{"key":"571_CR12","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1245\/s10434-009-0341-8","volume":"16","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Smigielski ME, et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol. 2009;16:1903\u201311.","journal-title":"Ann Surg Oncol"},{"key":"571_CR13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10434-999-0727-7","volume":"6","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727\u201331.","journal-title":"Ann Surg Oncol"},{"key":"571_CR14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/DCR.0b013e318202f026","volume":"54","author":"H Youssef","year":"2011","unstructured":"Youssef H, Newman C, Chandrakumaran K, et al. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54:293\u20139.","journal-title":"Dis Colon Rectum"},{"key":"571_CR15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/bjs.6235","volume":"95","author":"D Elias","year":"2008","unstructured":"Elias D, Honore C, Ciuchendea R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008;95:1164\u201371.","journal-title":"Br J Surg"},{"key":"571_CR16","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985\u201390.","journal-title":"Ann Oncol"},{"key":"571_CR17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.hoc.2005.09.005","volume":"19","author":"R Hassan","year":"2005","unstructured":"Hassan R, Alexander R. Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium. Hematol Oncol Clin North Am. 2005;19:1067\u201387. vi.","journal-title":"Hematol Oncol Clin North Am"},{"key":"571_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11864-000-0046-5","volume":"1","author":"RN Taub","year":"2000","unstructured":"Taub RN, Keohan ML, Chabot JC, et al. Peritoneal mesothelioma. Curr Treat Options Oncol. 2000;1:303\u201312.","journal-title":"Curr Treat Options Oncol"},{"key":"571_CR19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.annpat.2014.01.004","volume":"34","author":"E Mery","year":"2014","unstructured":"Mery E, Hommell-Fontaine J, Capovilla M, et al. Peritoneal malignant mesothelioma: review and recent data. Ann Pathol. 2014;34:26\u201333.","journal-title":"Ann Pathol"},{"key":"571_CR20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/030089160308900307","volume":"89","author":"YI Acherman","year":"2003","unstructured":"Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269\u201373.","journal-title":"Tumori"},{"key":"571_CR21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1179\/oeh.2005.11.3.254","volume":"11","author":"LS Welch","year":"2005","unstructured":"Welch LS, Acherman YI, Haile E, et al. Asbestos and peritoneal mesothelioma among college-educated men. Int J Occup Environ Health. 2005;11:254\u20138.","journal-title":"Int J Occup Environ Health"},{"key":"571_CR22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827\u201334.","journal-title":"Ann Oncol"},{"key":"571_CR23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.7326\/0003-4819-96-6-746","volume":"96","author":"AP Chahinian","year":"1982","unstructured":"Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med. 1982;96:746\u201355.","journal-title":"Ann Intern Med"},{"key":"571_CR24","first-page":"951","volume":"54","author":"JT Peterson Jr","year":"1984","unstructured":"Peterson Jr JT, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma. A review Cancer. 1984;54:951\u201360.","journal-title":"A review Cancer"},{"key":"571_CR25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/1097-0142(19810701)48:1<134::AID-CNCR2820480124>3.0.CO;2-4","volume":"48","author":"RH Riddell","year":"1981","unstructured":"Riddell RH, Goodman MJ, Moossa AR. Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer. 1981;48:134\u20139.","journal-title":"Cancer"},{"key":"571_CR26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.5858\/133.8.1317","volume":"133","author":"AN Husain","year":"2009","unstructured":"Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133:1317\u201331.","journal-title":"Arch Pathol Lab Med"},{"key":"571_CR27","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1245\/s10434-007-9475-8","volume":"14","author":"D Baratti","year":"2007","unstructured":"Baratti D, Kusamura S, Nonaka D, et al. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). Ann Surg Oncol. 2007;14:2790\u20137.","journal-title":"Ann Surg Oncol"},{"key":"571_CR28","first-page":"153","volume":"22","author":"D Baratti","year":"2008","unstructured":"Baratti D, Kusamura S, Sironi A, et al. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC). In Vivo. 2008;22:153\u20137.","journal-title":"In Vivo"},{"key":"571_CR29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ejso.2010.08.130","volume":"36","author":"D Baratti","year":"2010","unstructured":"Baratti D, Vaira M, Kusamura S, et al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur J Surg Oncol. 2010;36:1047\u201353.","journal-title":"Eur J Surg Oncol"},{"key":"571_CR30","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560\u20137.","journal-title":"J Clin Oncol"},{"key":"571_CR31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0021-7697(08)74654-4","volume":"145","author":"G Passot","year":"2008","unstructured":"Passot G, Cotte E, Brigand C, et al. Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. J Chir (Paris). 2008;145:447\u201353.","journal-title":"J Chir (Paris)"},{"key":"571_CR32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"65","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69\u201379.","journal-title":"Eur J Cancer"},{"key":"571_CR33","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237\u201342.","journal-title":"J Clin Oncol"},{"key":"571_CR34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10552-010-9525-6","volume":"21","author":"DJ Grant","year":"2010","unstructured":"Grant DJ, Moorman PG, Akushevich L, et al. Primary peritoneal and ovarian cancers: an epidemiological comparative analysis. Cancer Causes Control. 2010;21:991\u20138.","journal-title":"Cancer Causes Control"},{"key":"571_CR35","first-page":"1361","volume":"60","author":"JO Schorge","year":"2000","unstructured":"Schorge JO, Muto MG, Lee SJ, et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res. 2000;60:1361\u20134.","journal-title":"Cancer Res"},{"key":"571_CR36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jnci\/90.11.841","volume":"90","author":"JO Schorge","year":"1998","unstructured":"Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst. 1998;90:841\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"571_CR37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejso.2013.02.018","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Gilly FN, Baratti D, et al. Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. Eur J Surg Oncol. 2013;39:742\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"571_CR38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00000478-199106000-00001","volume":"15","author":"WL Gerald","year":"1991","unstructured":"Gerald WL, Miller HK, Battifora H, et al. Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surg Pathol. 1991;15:499\u2013513.","journal-title":"Am J Surg Pathol"},{"key":"571_CR39","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1245\/s10434-014-4123-6","volume":"22","author":"C Honore","year":"2015","unstructured":"Honore C, Amroun K, Vilcot L, et al. Abdominal desmoplastic small round cell tumor: multimodal treatment combining chemotherapy, surgery, and radiotherapy is the best option. Ann Surg Oncol. 2015;22:1073\u20139.","journal-title":"Ann Surg Oncol"},{"key":"571_CR40","doi-asserted-by":"crossref","first-page":"680126","DOI":"10.1155\/2014\/680126","volume":"2014","author":"CK Lettieri","year":"2014","unstructured":"Lettieri CK, Garcia-Filion P, Hingorani P. Incidence and outcomes of desmoplastic small round cell tumor: results from the surveillance, epidemiology, and end results database. J Cancer Epidemiol. 2014;2014:680126.","journal-title":"J Cancer Epidemiol"},{"key":"571_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-3-14","volume":"3","author":"HH Wong","year":"2013","unstructured":"Wong HH, Hatcher HM, Benson C, et al. Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature. Clin Sarcoma Res. 2013;3:14.","journal-title":"Clin Sarcoma Res"},{"key":"571_CR42","first-page":"2837","volume":"54","author":"M Ladanyi","year":"1994","unstructured":"Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994;54:2837\u201340.","journal-title":"Cancer Res"},{"key":"571_CR43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02190536","volume":"417","author":"I Lausen","year":"1990","unstructured":"Lausen I, Jensen O, Andersen E, Lindahl F. Disseminated peritoneal leiomyomatosis with malignant change, in a male. Vichows Archiv A Pathol Anat. 1990;417:173\u20135.","journal-title":"Vichows Archiv A Pathol Anat"},{"key":"571_CR44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1440-1827.2003.01452.x","volume":"53","author":"T Yamaguchi","year":"2003","unstructured":"Yamaguchi T, Imamura Y, Yamamoto T, Fukuda M. Leiomyomatosis peritonealis disseminata with malignant change in a man. Pathol Int. 2003;53:179\u201385.","journal-title":"Pathol Int"},{"key":"571_CR45","first-page":"79","volume":"9","author":"RH Bourgain","year":"1994","unstructured":"Bourgain RH, Paubert-Braquet M, Shen S, et al. An optoelectronic registration method as applied to PAF-mediated hydrogen peroxide induced arterial thrombosis. J Lipid Mediat Cell Signal. 1994;9:79\u201388.","journal-title":"J Lipid Mediat Cell Signal"},{"key":"571_CR46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004347-198201000-00008","volume":"1","author":"FA Tavassoli","year":"1982","unstructured":"Tavassoli FA, Norris HJ. Peritoneal leiomyomatosis (leiomyomatosis peritonealis disseminata): a clinicopathologic study of 20 cases with ultrastructural observations. Int J Gynecol Pathol. 1982;1:59\u201374.","journal-title":"Int J Gynecol Pathol"},{"key":"571_CR47","first-page":"447","volume":"54","author":"KG Kratz","year":"2009","unstructured":"Kratz KG, Santillan A, Gu M, Bristow RE. Radical surgical cytoreduction of progressive leiomyomatosis peritonealis disseminata: a case report. J Reprod Med. 2009;54:447\u201350.","journal-title":"J Reprod Med"},{"key":"571_CR48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.annpat.2014.01.008","volume":"34","author":"L Villeneuve","year":"2014","unstructured":"Villeneuve L, Isaac S, Glehen O, et al. The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists. Ann Pathol. 2014;34:4\u20138.","journal-title":"Ann Pathol"},{"key":"571_CR49","unstructured":"Agency for Healthcare Research and Quality. Registries for evaluating patient outcomes: a user\u2019s guide. Rockville: AHRQ Publication No. 13(14)-EHC111; 2014."},{"key":"571_CR50","unstructured":"Guidance for Industry Part 11, Electronic records; electronic signatures \u2014 scope and application. In Services USDoHaH (ed). Food and Drug Administration August: 2003."},{"key":"571_CR51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.2009.1092","volume":"302","author":"NA Dreyer","year":"2009","unstructured":"Dreyer NA, Garner S. Registries for robust evidence. JAMA. 2009;302:790\u20131.","journal-title":"JAMA"},{"key":"571_CR52","volume-title":"Joint declaration of 10 key principles for rare disease patient registries","author":"EURORDIS, NORD, CORD","year":"2012","unstructured":"EURORDIS, NORD, CORD. Joint declaration of 10 key principles for rare disease patient registries. 2012."},{"key":"571_CR53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","volume":"40","author":"NJ Carr","year":"2016","unstructured":"Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified delphi process. Am J Surg Pathol. 2016;40:14\u201326.","journal-title":"Am J Surg Pathol"},{"key":"571_CR54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.humpath.2016.04.015","volume":"55","author":"P Chirac","year":"2016","unstructured":"Chirac P, Maillet D, Lepretre F, et al. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Hum Pathol. 2016;55:72\u201382.","journal-title":"Hum Pathol"},{"key":"571_CR55","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1245\/s10434-013-3077-4","volume":"20","author":"J Hommell-Fontaine","year":"2013","unstructured":"Hommell-Fontaine J, Isaac S, Passot G, et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol. 2013;20:3892\u20138.","journal-title":"Ann Surg Oncol"},{"key":"571_CR56","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ejso.2016.03.015","volume":"42","author":"L Villeneuve","year":"2016","unstructured":"Villeneuve L, Thivolet A, Bakrin N, et al. A new internet tool to report peritoneal malignancy extent. PeRitOneal malignancy stage evaluation (PROMISE) application. Eur J Surg Oncol. 2016;42:877\u201382.","journal-title":"Eur J Surg Oncol"},{"key":"571_CR57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.annpat.2014.01.011","volume":"34","author":"NJ Carr","year":"2014","unstructured":"Carr NJ. Current concepts in pseudomyxoma peritonei. Ann Pathol. 2014;34:9\u201313.","journal-title":"Ann Pathol"},{"key":"571_CR58","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","volume":"117","author":"TD Yan","year":"2011","unstructured":"Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011;117:1855\u201363.","journal-title":"Cancer"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0571-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T10:56:04Z","timestamp":1658660164000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0571-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0571-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]},"article-number":"37"}}